Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Noglux (Bioksan, eda930)
- Development stage
- Unknown
- Lead developer
- Bioksan
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Noglux is a combination nutraceutical developed by Bioksan for the management of prediabetes, metabolic syndrome, obesity, and reactive hypoglycemia. The formulation contains a standardized extract of white mulberry leaf (Reducose), which is rich in 1-deoxynojirimycin and acts as a competitive alpha-glucosidase inhibitor to slow carbohydrate absorption and blunt postprandial glucose spikes. It also includes fenugreek extract, an activator of AMP-activated protein kinase (AMPK) that enhances insulin sensitivity, alongside the prebiotic fiber inulin and the probiotic strain Lactiplantibacillus plantarum A7 to support gut microbiota health. Essential micronutrients, including niacin, chromium, and zinc, are incorporated to support insulin synthesis and macronutrient metabolism. Clinical studies have demonstrated that Noglux significantly reduces insulin resistance, improves lipid profiles, and decreases the frequency of hypoglycemic episodes in patients with postprandial reactive hypoglycemia.
- Brand names
- Noglux
- Other names
- Noglux de Bioksanwhite mulberry + fenugreek + inulin + niacin + chromium + zinc + Lactiplantibacillus plantarum A7
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)Sucrase-Isomaltase
Beyond the preview
Go deeper on Noglux (Bioksan, eda930).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noglux (Bioksan, eda930).